Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing

[1]  E. Boerwinkle,et al.  dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.

[2]  E. H. Margulies,et al.  Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma , 2011, Nature Genetics.

[3]  Jimmy Lin,et al.  Analysis of the disintegrin‐metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma , 2011, Human mutation.

[4]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[5]  E. Boerwinkle,et al.  dbNSFP: A Lightweight Database of Human Nonsynonymous SNPs and Their Functional Predictions , 2011, Human mutation.

[6]  P. Pandolfi,et al.  Haplo‐insufficiency: a driving force in cancer , 2011, The Journal of pathology.

[7]  C. Der.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2010 .

[8]  Mary Goldman,et al.  The UCSC Genome Browser database: update 2011 , 2010, Nucleic Acids Res..

[9]  Jimmy Lin,et al.  Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma , 2010, Molecular Cancer Research.

[10]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[11]  Jana Marie Schwarz,et al.  MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.

[12]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[13]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[14]  S. Nelson,et al.  BFAST: An Alignment Tool for Large Scale Genome Resequencing , 2009, PloS one.

[15]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[16]  Justin C. Fay,et al.  Identification of deleterious mutations within three human genomes. , 2009, Genome research.

[17]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[18]  Hiromi Nakamura,et al.  ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis , 2009, The EMBO journal.

[19]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[20]  M. Christmann,et al.  Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53 , 2009, British Journal of Cancer.

[21]  T. Ryken,et al.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. , 2008, Cancer research.

[22]  D. Bozyczko‐Coyne,et al.  Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. , 2008, Journal of Medicinal Chemistry.

[23]  D. Kaplan,et al.  Mice lacking both mixed-lineage kinase genes Mlk1 and Mlk2 retain a wild type phenotype , 2008, Cell cycle.

[24]  H. Ichijo,et al.  Apoptosis signal-regulating kinase 1 in stress and immune response. , 2008, Annual review of pharmacology and toxicology.

[25]  S. Knapp,et al.  Structural and Functional Characterization of the Human Protein Kinase ASK1 , 2007, Structure.

[26]  Adam Yao,et al.  PrimerZ: streamlined primer design for promoters, exons and human SNPs , 2007, Nucleic Acids Res..

[27]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[28]  N. Hayward,et al.  Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. , 2007, Cancer research.

[29]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[30]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[31]  A. Konagurthu,et al.  MUSTANG: A multiple structural alignment algorithm , 2006, Proteins.

[32]  David Haussler,et al.  New Methods for Detecting Lineage-Specific Selection , 2006, RECOMB.

[33]  Terrence S. Furey,et al.  The UCSC Genome Browser Database: update 2006 , 2005, Nucleic Acids Res..

[34]  Karla K Kopec,et al.  Phosphoregulation of mixed-lineage kinase 1 activity by multiple phosphorylation in the activation loop. , 2004, Biochemistry.

[35]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[36]  Markus Ringnér,et al.  Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.

[37]  A. Paige.  Redefining tumour suppressor genes: exceptions to the two-hit hypothesis , 2003, Cellular and Molecular Life Sciences CMLS.

[38]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[39]  A. Bode,et al.  Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. , 2002, Cancer research.

[40]  Zhiheng Xu,et al.  The MLK Family Mediates c-Jun N-Terminal Kinase Activation in Neuronal Apoptosis , 2001, Molecular and Cellular Biology.

[41]  L. Johnson,et al.  The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition , 1997, The EMBO journal.

[42]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[43]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[44]  O. Rath,et al.  MAP kinase signaling pathways in cancer. Oncogene , 2007 .

[45]  Vincent B. Chen,et al.  Acta Crystallographica Section D Biological , 2001 .

[46]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..